Kraig Biocraft Secures Capital, Signs R&D Agreement

The SEC recently declared effective Lansing, Mich.-based Kraig Biocraft Laboratories’ registration statement with Calm Seas Capital. This approval secures up to $7.5 million over the next two years for research, development and production purposes. In other company news, Kraig recently signed a cooperative research and development agreement with the University of Notre Dame to advance the speed of development for its transgenic silkworm technology. In addition, the company generated a batch of finished Monster Silk using its pilot-scale production facility. The materials produced are used to assess the technology and evaluate performance for potential market channel partners.

July/August 2015